Stockreport

Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference [Yahoo! Finance]

Gain Therapeutics, Inc.  (GANX) 
PDF and decreases in DOPA decarboxylase, suggesting a GCase stabilizing "gain-of-function" effect and biological proof-of-concept. Gain expects to start Phase 2 in Q3 pend [Read more]